Biogen Idec, Inc. (Massachusetts) and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs

WESTON, Mass. & ZURICH--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43. These targets are believed to be relevant for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). Biogen Idec will make an initial payment of $32.5 million and up to $395 million in contingent payments.